China’s Shanghai Henlius Biotech said that it “made the most out of recently launched products” in 2020, as the company announced a 546% increase in revenue to RMB587.6m ($89.8m) compared to 2019. The company said that 2020 marked a meaningful year for Henlius, as it “gathered pace in commercialization and continued the momentum for innovation.”
“The overall increase was mainly driven by the sales revenue from the launched products, R&D services provided to customers and...